Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9

First published 10/07/2020

Last updated 02/07/2024

EU PAS number:

EUPAS36135

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

V503-056_Redacted Protocol red

English (9.45 MB - PDF)View document

Study results

Study results

V503-056-CSR- HPV PMC G9 effectiveness study report_final redaction

English (1.06 MB - PDF)View document

V503-056_Combined G4 and G9 Report with Cover Letter_final redaction

English (1.29 MB - PDF)View document

Study report

Other information